Hillstar Bio

Hillstar Bio formed a Clinical Advisory Board to guide the development of HSB-101, its lead therapy targeting TRBV9 for axial spondyloarthritis.

Shiva Krupa, Ph.D., MBA, also joins as Vice President of Program Management

Proceeds to fund advancement of the company’s lead TRBV9 program through clinical proof-of- concept study in axial spondyloarthritis and progression of broader pipeline

Hillstar Bio is pioneering precision immunotherapies that target and deplete pathogenic immune cells, aiming to reset the immune system and transform treatment for autoimmune diseases.

Hillstar Bio outlines its data collection and privacy practices for website visitors.

Hillstar Bio assembles a Clinical Advisory Board of physician-scientists specializing in spondyloarthritis and rheumatology. The board will guide development of **HSB-101**, the company’s lead therapy targeting **TRBV9** in axial spondyloarthritis (AxSpA). Hillstar focuses on precision immunology treatments for autoimmune diseases.

Sep 2025Hillstar Bio | Transforming Autoimmune TreatmentNews article

Hillstar Bio appoints **Maude Tessier, Ph.D.** as Chief Operating Officer to strengthen its precision immunotherapy pipeline. The company also hires **Shiva Krupa, Ph.D., MBA**, as Vice President of Program Management, expanding its leadership team to accelerate development efforts.

May 2025Hillstar Bio | Transforming Autoimmune TreatmentNews article

Hillstar Bio secures **$67 million in Series A funding** to advance its **TRBV9 program**, targeting a clinical proof-of-concept study for axial spondyloarthritis. The capital also supports development of the company’s broader pipeline of therapeutic candidates. The funding marks a key milestone for Hillstar Bio’s early-stage drug development efforts.

Mar 2025Hillstar Bio | Transforming Autoimmune TreatmentNews article

Hillstar Bio secures **$67 million in Series A funding** to advance precision immunotherapies targeting autoimmune diseases. The round includes investors like **Droia Ventures, Frazier Life Sciences, Novo Holdings, LifeArc Ventures, and Hummingbird Bioscience**. The company focuses on next-generation treatments leveraging precision immunology to transform autoimmune care.

Mar 2025Droia Ventures – Investing in ImpactNews article